CLAIM #43302 · Merck & Company Inc (MRK) · 2023Q2 earnings call · Aug 1, 2023 · due Dec 31, 2026
“What I do think is highly likely is that we will be able to see this resolved by the time we get into the 2026 time frame.”
Rob Davis · CEO
How to check this claim
Look at: Legal resolution status of the company's IRA lawsuit (district/circuit/Supreme Court ruling or settlement)
It came true if: A final or binding court ruling (or resolution) on the litigation is reported by year-end 2026
Where: Company legal disclosures (10-K/10-Q litigation section) or news reports on court rulings
In context
“g forward and our belief is that the provisions, particularly the negotiation provision of the IRA is in violation of both the fifth and the first amendment of the constitution and is not a good policy. That's what brought us to bring to suit. As we look forward, we're going to take this to the fullest, which means we'll take it through district court, and if need be, in the circuit court and ultimately to the Supreme Court. So really, that's the strategy. I don't want to comment on other companies and whether you're going to see additional companies come in beyond the four that are in now. As far as any kind of triggers to watch for, not really. Because while obviously we have set dates for the initial discovery and some of the initial hearings, this is going to take a while to play out. What I do think is highly likely is that we will be able to see this resolved by the time we get into the 2026 time frame. That's really what we're thinking about and moving through the various courts as needed. But I don't really think you're going to see any large indicator in the near term. This is a longer-term play. Peter Dannenbaum: Thanks, Geoff. Next question please, Cedric. Operator: Yes. Our next question comes from Mohit Bansal with Wells Fargo. Your line is open. Mohit Bansal: Okay. Thanks very much for taking my question. My question is regarding the onetime items. So Caroline, you mentioned regarding China for GARDASIL, as well as KEYTRUDA in the U.S. Would you be able to quantify this a little bit? Just trying to understand the magnitude of how much is impacted by those onetime items. Thank you. Caroline Litchfield: Yes, of course, Mohit. Thank you for the question. So first, talking about GARD”
Verify independently
SEC filings for MRK ↗ · Claim quote is verbatim from the 2023Q2 earnings call.